BrickBio preclinical-stage biopharmaceutical company Secures an Investment from Samsung Ventures. The latest investment reflects Samsung’s commitment to discover and explore new opportunities in biopharmaceuticals to address unmet therapeutic needs.
Samsung affiliates will work with BrickBio to evaluate, manufacture, and develop advanced molecules and therapies using BrickBio’s proprietary protein engineering technology for antibody-drug conjugates (ADCs), AAV gene therapy, and other modalities.
Read also – NYC-based BigID Secures $60Million in Growth Funding
It’s technology uses an expanded genetic code to incorporate synthetic amino acids into proteins, all completed within a living cell. These synthetic amino acids enable the creation of precision biologics, an exciting new class of therapeutics with broad application and potential.
John Boyce, the Chief Executive Officer and Co-Founder of BrickBio and Tiger Gene said, “We’re pleased to receive this support from Samsung, as well as the recognition of the potential for our advanced protein engineering technology to provide novel solutions for challenging medical conditions, We look forward to using these proceeds to further our efforts in advancing our ADC candidates toward the clinic.”
Ho Sung Cho, the Executive Vice President and Head of Early Research and Development of Samsung Bioepis said, “BrickBio’s robust expanded genetic code in mammalian cells offer the potential to create molecules and therapies to address unmet needs,”.
BrickBio’s innovation engine continues to expand the preclinical pipeline by discovering new and valuable programs that take full advantage of its technologies.
Read also – CA-based Superlinked Secures $9.5Million in Seed Funding
These novel programs have the potential to address a wide range of diseases with new or improved mechanisms of action, providing the company with a rich set of programs to develop internally and/or in partnership with leading pharmaceutical companies.
About BrickBio, Inc.
BrickBio Inc., a Boston-based biotechnology company, empowers next-generation unnatural amino acid coupled protein conjugation with its site-specific and site-selective platform. The platform technology spans prokaryotic and eukaryotic expression systems, enabling the development of unique biologics and protein therapeutics with enhanced characteristics, including improvements to half-life, dosage and efficacy.
